𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sodium oxybate in the treatment of binge eating disorder: An open-label, prospective study

✍ Scribed by McElroy, Susan L. ;Guerdjikova, Anna I. ;Winstanley, Erin L. ;O'Melia, Anne M. ;Mori, Nicole ;Keck, Paul E. ;Hudson, James I.

Publisher
Wiley (John Wiley & Sons)
Year
2011
Tongue
English
Weight
125 KB
Volume
44
Category
Article
ISSN
0276-3478

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Duloxetine in the treatment of adolescen
Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open-label study
✍ Javad Mahmoudi-Gharaei; Nasrin Dodangi; Mehdi Tehrani-Doost; Toktam Faghihi πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 90 KB πŸ‘ 1 views

Objective The main aim of this study was to explore the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in the treatment of adolescents with attention deficit/hyperactivity disorder (ADHD). Methods Seventeen adolescents aged 11-18 years, diagnosed with ADHD, par

The efficacy of reboxetine in the treatm
The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study
✍ P. N. Dannon; I. Iancu; L. Grunhaus πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 57 KB πŸ‘ 1 views

## Abstract ## Background and Objective Selective serotonin reuptake inhibitors (SSRIs) are currently the first‐line treatment for panic disorder, although up to 30% of patients either do not respond to SSRIs or withdraw due to adverse events. Reboxetine, a selective norepinephrine reuptake inhibi

Duloxetine in the treatment of irritable
Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study
✍ Brian P. Brennan; Kate V. Fogarty; Jacqueline L. Roberts; Karina A. Reynolds; Ha πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 94 KB πŸ‘ 1 views

## Abstract ## Objective To assess the efficacy of duloxetine for irritable bowel syndrome (IBS). ## Methods We conducted an open‐label 12‐week trial of duloxetine 60 mg daily in 15 patients with IBS without concurrent major depressive disorder. The primary outcome measure was average abdominal